Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
复制标题
DOI：
10.1161/circulationaha.122.061559
复制
发表时间：
2023-02-14
期刊：
影响因子：
37.8
通讯作者：
Lindley, Kathryn J.
中科院分区：
文献类型：
--
作者：
Cho, Leslie;Kaunitz, Andrew M.;Lindley, Kathryn J.
月经激素治疗（HT）在过去被广泛使用，但随着开创性的一级和二级预防试验的发表，报告了联合雌激素-孕酮的过度心血管风险，HT的使用显着下降。然而，在过去的20年里，人们已经了解到HT使用的时间与年龄和绝经后时间，HT给药途径和心血管疾病风险之间的关系。四个主要的医学协会推荐HT用于治疗更年期妇女的更年期症状。在这种情况下，这项审查，由美国心脏病学会心血管疾病妇女委员会，沿着与领先的妇科医生，妇女的健康内科医生，内分泌学家，旨在提供指导HT的使用，包括选择患者和HT配方，重点是照顾有症状的妇女心血管疾病的风险。
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.